Excelsus Structural Solutions SPRL, founded in March 2012 in Brussels, Belgium, was established as a spin-off from the Paul Scherrer Institute (PSI), Switzerland's largest federal research center for natural and engineering sciences. With its main offices in Brussels, the company primarily operated at the PSI synchrotron facility in Switzerland. Excelsus Structural Solutions SPRL ceased operations in September 2023.
In February 2014, Excelsus Structural Solutions (Swiss) AG was founded in Switzerland to facilitate the ESS team's access to synchrotron laboratories and foster collaboration with local scientists. Since April 2016, Excelsus Structural Solutions (Swiss) AG has been part of Switzerland Innovation PARK INNOVAARE. Since April 2016, Excelsus Structural Solutions (Swiss) AG is part of Switzerland Innovation PARK INNOVAARE. More on ESS (Swiss) AG transition to Switzerland Innovation PARK INNOVAARE. Interview to founder Dr Fabia Gozzo.
Excelsus Structural Solutions offers easy and affordable access to unique Synchrotron-based characterization tools developed at the Paul Scherrer Institute, to enhance the selection, development and manufacturing of high-quality (bio)pharmaceutical products.
Excelsus Structural Solutions Team of experienced synchrotron scientists with many years of experience in ab-initio structural solution, qualitative and quantitative phase analysis applied to pharmaceuticals will assist you in the definition of the best strategy to takle your specific problem, the conception of the appropriate experimental plan and the development and realization of it. Excelsus' Team will take care of sample preparation, definition of the most appropriate experimental conditions and protocol, data collection, reprocessing, analysis and interpretation and deliver to you a detailed experimental report that suits your specific needs, as defined by you.
Excelsus Structural Solutions team will make available to you the latest advanced Synchrotron X-Ray Powder Diffraction experimental data collection data analysis strategies that have made it possible the detection and quantification of traces of minority phases as low as 0.01% wt in organic pharmaceutical compounds. Level of Detection (LoD) and Level of Quantification (LoQ) as low as 0.01% wt have been recently demonstrated in organic pharmaceutical compounds when using unconventional beamline optics set up developed by Excelsus Team. MORE on 0.01% wt LoD.
The experience of highly qualified professionals in our team providing engineering and scientific services to the industry, while handling proprietary information with high confidentiality standards, is significantly greater than the years that we have been in business.
A network of scientists worldwide allows us to be uniquely positioned to broaden our services with the high standards of Excelsus.
KEYWORDS: Synchrotron X-Ray Powder Diffraction, Pharmaceuticals, Quantitative Phase Analysis, Qualitative Phase Anlaysis, Low Level of Detection, Low Level of Quantification
